Floatz logo

Milatuzumab

Lymphoma, B-Cell

Gilead Sciencesmonoclonal_antibodyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
73/ 100

Competitive context

51 Active assets in the Lymphoma, B-Cell cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mwanasha Merrill, MD
Phase 4BB
Cyclophosphamide
Swiss Cancer Institute
Phase 4BB
cd19-ucart
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4BB
(+)-VINCRISTINE
Mwanasha Merrill, MD
Phase 4BB
Inno-206
Mwanasha Merrill, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Milatuzumab is also rated in:

NHLDormant
B
Indicative ·
58 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
Lymphoma, Large-CellDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →